Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial

Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial

(2017) David A Margolis et al.   LANCET

Broadly neutralizing antibodies to prevent HIV-1

(2017) Myron S. Cohen et al.   SCIENCE

Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial

(2017) Martin Markowitz et al.   Lancet HIV

Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial

(2016) Sheena McCormack et al.   LANCET

Safety and Efficacy of a Dapivirine Vaginal Ring for HIV Prevention in Women

(2016) Annalene Nel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Use of a Vaginal Ring Containing Dapivirine for HIV-1 Prevention in Women

(2016) Jared M. Baeten et al.   NEW ENGLAND JOURNAL OF MEDICINE

Preexposure Prophylaxis for HIV Infection Integrated With Municipal- and Community-Based Sexual Health Services

(2016) Albert Y. Liu et al.   JAMA Internal Medicine

Defining success with HIV pre-exposure prophylaxis

(2015) Jessica E. Haberer et al.   AIDS

Pharmacokinetics of Long-Acting Tenofovir Alafenamide (GS-7340) Subdermal Implant for HIV Prophylaxis

(2015) Manjula Gunawardana et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial

(2015) David A Margolis et al.   LANCET INFECTIOUS DISEASES

On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection

(2015) Jean-Michel Molina et al.   NEW ENGLAND JOURNAL OF MEDICINE

The long-acting integrase inhibitor GSK744 protects macaques from repeated intravaginal SHIV challenge

(2015) J. Radzio et al.   Science Translational Medicine

A long-acting integrase inhibitor protects female macaques from repeated high-dose intravaginal SHIV challenge

(2015) Chasity D. Andrews et al.   Science Translational Medicine

Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study

(2014) Robert M Grant et al.   LANCET INFECTIOUS DISEASES

Long-Acting Integrase Inhibitor Protects Macaques from Intrarectal Simian/Human Immunodeficiency Virus

(2014) C. D. Andrews et al.   SCIENCE

Committee Opinion No 579

(2013)   OBSTETRICS AND GYNECOLOGY

Long-acting injectable antiretrovirals for HIV treatment and prevention

(2013) William R. Spreen et al.   Current Opinion in HIV and AIDS

Antiretroviral Preexposure Prophylaxis for Heterosexual HIV Transmission in Botswana

(2012) Michael C. Thigpen et al.   NEW ENGLAND JOURNAL OF MEDICINE

Antiretroviral Prophylaxis for HIV Prevention in Heterosexual Men and Women

(2012) Jared M. Baeten et al.   NEW ENGLAND JOURNAL OF MEDICINE

State of the art of nanocrystals – Special features, production, nanotoxicology aspects and intracellular delivery

(2011) Rainer H. Müller et al.   EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS

Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men

(2010) Robert M. Grant et al.   NEW ENGLAND JOURNAL OF MEDICINE